共 38 条
- [1] Atezolizumab (A), cobimetinib (C), and vemurafenib (V) in patients (pts) with BRAFV600 mutation-positive melanoma with central nervous system (CNS) metastases (mets): Final results and exploratory biomarker analysis from the phase 2 TRICOTEL studyJOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Dummer, ReinhardLevesque, MitchellBellini, ElisaChen, MarissaHu, YouyouWong, TiffanyStassen, KatjaDuhard, PaulineYan, YibingTawbi, Hussein A.
- [2] A phase II study evaluating atezolizumab (A), cobimetinib (C), and vemurafenib (V) in patients (pts) with BRAF-mutant melanoma and central nervous system (CNS) metastases (mets).JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)Queirolo, Paolade la Cruz Merino, LuisAbajo Guijarro, Ana MariaTawbi, Hussein Abdul-HassanDummer, Reinhard
- [3] Evaluation of atezolizumab (A), cobimetinib (C), and vemurafenib (V) in previously untreated patients with BRAFV600 mutation-positive advanced melanoma: Primary results from the phase 3 IMspire150 trialCANCER RESEARCH, 2020, 80 (16)McArthur, A.Stroyakovskiy, DaniilGogas, HelenRobert, CarolineLewis, KarlProtsenko, SvetlanaPereira, RodrigoEigentler, ThomasRutkowski, PiotrDemidov, LevManikhas, Georgy MoiseevichYan, YibingHuang, K. C.Uyei, AnneMcNally, VirginaGutzmer, RalfAscierto, Paolo
- [4] Vemurafenib in patients with BRAFV600 mutation-positive melanoma with symptomatic brain metastases: Final results of an open-label pilot studyEUROPEAN JOURNAL OF CANCER, 2014, 50 (03) : 611 - 621Dummer, ReinhardGoldinger, Simone M.Turtschi, Christian P.Eggmann, Nina B.Michielin, OlivierMitchell, LadaVeronese, LuisaHilfiker, Paul ReneFelderer, LeaRinderknecht, Jeannine D.
- [5] Time to central nervous system (CNS) metastases (mets) with atezolizumab (A) or placebo (P) combined with cobimetinib (C) plus vemurafenib (V) in the phase Ill IMspire150 study.JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)Ascierto, Paolo AntonioRobert, CarolineLewis, Karl D.Munhoz, RodrigoLiszkay, GabriellaMerino, Luis de la CruzOlah, JuditQueirolo, PaolaMackiewicz, JacekLi, HaochengZhu, QianMcNally, V.Mckenna, Edward FrancisGutzmer, RalfMcArthur, Grant A.
- [6] Efficacy and safety of cobimetinib (C) combined with vemurafenib (V) in patients (pts) with BRAFV600 mutation-positive metastatic melanoma: analysis from the 4-year extended follow-up of the phase 3 coBRIM studyJOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)Dreno, BrigitteAscierto, Paolo AntonioMcArthur, Grant A.Atkinson, VictoriaLiszkay, GabriellaDi Giacomo, Anna MariaMandala, MarioDemidov, Lev V.Stroyakovskiy, DaniilThomas, LucDe la Cruz-Merino, LuisDutriaux, CarolineGarbe, ClausRooney, Isabelle AnneHsu, Jessie J.Park, EricaRibas, AntoniLarkin, James M. G.
- [7] Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study LANCET ONCOLOGY, 2023, 24 (04): : E145 - E145
- [8] Overall survival (OS) with first-line atezolizumab (A) or placebo (P) in combination with vemurafenib (V) and cobimetinib (C) in BRAFV600 mutation-positive advanced melanoma: Second interim OS analysis of the phase 3 IMspire150 study.JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)McArthur, Grant A.Gutzmer, RalfStroyakovskiy, DaniilGogas, HelenRobert, CarolineProtsenko, SvetlanaPereira, Rodrigo PerezEigentler, ThomasRutkowski, PiotrDemidov, Lev V.Zhukova, Natalia V.Schachter, JacobYan, YibingCaro, IvorHertig, ChristianXue, ClorisKusters, LiekeAscierto, Paolo AntonioLewis, Karl D.
- [9] Efficacy and safety of sequencing with vemurafenib (V) plus cobimetinib (C) followed by atezolizumab (Atezo) in patients (pts) with advanced BRAFV600-positive melanoma: Interim analysis of the ImmunoCobiVem study.JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Schadendorf, DirkGogas, HelenSekulovic, Lidija KandolfMeier, Friedegund ElkeEigentler, ThomasSimon, Jan-ChristophTerheyden, Patrick Andres MaximilianGesierich, Anja HeikeHerbst, Rudolf AlexanderKahler, Katharina C.Ziogas, Dimitrios C.Mijuskovic, ZeljkoGarzarolli, MarleneGarbe, ClausRoesch, AlexanderUgurel, SelmaGutzmer, RalfGrob, Jean-JacquesZimmer, LisaLivingstone, Elisabeth
- [10] Time to development of central nervous system (CNS) metastases (mets) with atezolizumab (A) or placebo (P) combined with vemurafenib (V) plus cobimetinib (C): Updated results from the phase III IMspire150 studyANNALS OF ONCOLOGY, 2022, 33 (07) : S917 - S918Lewis, K.Robert, C.Munhoz, R. RamellaLiszkay, G.Merino, L. De la CruzOlah, J.Queirolo, P.Mackiewicz, J.Li, H.Zhu, Q.Hertig, C.Paranthaman, N.McKenna, E. F.Gutzmer, R.McArthur, G.Ascierto, P. A.